Physician profile
Gary M Koritzinsky
NPI 1366472128
$2,402.15
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $264 · 2021: $158 · 2023: $19.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $353.22 | 2019-2020 | |
| Abbvie INC. | $233.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $229.69 | 2019 | |
| Lilly USA, LLC | $228.25 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $195.75 | 2019-2020 | |
| Amarin Pharma, INC. | $144.90 | 2019-2021 | |
| Celgene Corporation | $106.52 | 2019 | |
| Allergan, INC. | $100.76 | 2019-2020 | |
| Radius Health, INC. | $94.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $81.95 | 2019 | |
| Glaxosmithkline, LLC. | $76.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.30 | 2019 | |
| Ucb, INC. | $57.56 | 2019 | |
| Novo Nordisk INC | $46.50 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.04 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $44.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.36 | 2019 | |
| Merck Sharp & Dohme LLC | $38.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.79 | 2019 | |
| Mallinckrodt Enterprises LLC | $29.33 | 2019 | |
| Horizon Therapeutics Plc | $26.52 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.60 | 2021 | |
| Assertio Therapeutics, INC. | $20.75 | 2019 | |
| Astellas Pharma US INC | $19.81 | 2023 | Veozah |
| Sanofi Pasteur INC. | $19.24 | 2019 | |
| Aytu Biopharma, INC. | $17.64 | 2019 | |
| Hikma Pharmaceuticals USA | $16.13 | 2019 | |
| Pfizer INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Koritzinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.